Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Nasdaq, S&P 500 climb ahead of keenly awaited Fed decision
- Oil slips as Saudi Arabia offers more crude via Oman; diesel near record high
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Stocks tend to rise after the Fed starts to hike
- Raymond James Downgrades Ascendis Pharma (ASND) to Outperform
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Evercore ISI Upgrades Vertex (VRTX) to Outperform
April 11, 2024 6:01 AM EDTEvercore ISI analyst Liisa Bayko upgraded Vertex (NASDAQ: VRTX) from In Line to Outperform with a price target of $438.00.
The analyst comments "In a surprise move (but makes all the sense now), VRTX is acquiring ALPN, a company focused on developing protein-based... More
